Vancouver, British Columbia (ots/PRNewswire) – Clínica Universidad de Navarra has completed a randomized controlled trial of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated Covid-19 patients with early symptoms of Covid-19.
“Early results from this clinical trial indicate that treatment with nasal photodisinfection rapidly and significantly suppresses SARS-CoV-2 virus replication and infectivity in the nasal cavity of previously vaccinated individuals. This study confirms the early work done by Canadian clinicians during the pandemic,” commented Dr. A. Fernandez-Montero, one of the three principal investigators responsible for the clinical trial at Clínica Universidad de Navarra. “We are in the process of submitting our results for publication and look forward to discussing these and other important results of the study in the near future.”
Photodisinfection rapidly destroys pathogens such as viruses, bacteria and fungi, including resistant strains. This broad-spectrum approach targets the primary source of infection as well as bacterial cofactors that may also contribute to significant comorbidity. Nasal photodisinfection has been used in Canadian hospitals over the past decade to significantly reduce hospital-acquired infections. Ondine’s photodisinfection is a platform technology being developed for a variety of conditions, including decolonization prior to surgical procedures, treatment of burns, wounds, ventilator-associated pneumonia and chronic sinusitis.
“The increasing rates of Covid-19 due to rapidly evolving SARS-CoV-2 variants underscore the importance of our broad-spectrum nasal decolonization research. We are pleased that the initial results of the Clínica Universidad de Navarra clinical trial in vaccinated individuals confirm the findings of studies at Sunnybrook Hospital (Toronto) and the University of Coimbra (Portugal), as well as in Canadian meat processing plants,” said Dr. Nicolas Loebel, president of Ondine.
“Our goal is to be able to provide cost-effective Covid-19 treatment and prophylaxis to help our communities deal with SARS-CoV-2 variants and other emerging threats. We thank the team at Clínica Universidad de Navarra for their expertise, facilities, and exceptional support in conducting this important study under pandemic conditions. The study adds to the growing body of evidence supporting positive outcomes of nasal photodisinfection in the prevention and treatment of Covid-19.”
Information on Ondine Biomedical Inc.
Ondine Biomedical Inc. has developed a patented platform technology called photodisinfection that can be used to prevent and treat infections, including those caused by multidrug-resistant strains and emerging bacterial, fungal and viral pathogens.
The company has seven products in the pipeline at various stages of development, including the treatment of chronic rhinosinusitis, burns and wounds; disinfection of endotracheal tubes to reduce the incidence of pneumonia associated with ventilators; and most recently, the development of a topical upper respiratory antiviral therapy to reduce transmission of SARS-CoV-2. Steriwave, the company’s nasal decolonization product, has been used safely and effectively in Canadian hospitals for over a decade to prevent hospital-acquired infections.
For more information, visit: www.ondinebio.com
OTS-ORIGINAL TEXT PRESS RELEASE UNDER EXCLUSIVE CONTENT RESPONSIBILITY OF THE SENDER. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH and the respective sender.
The post Suppression of SARS-CoV-2 replication and infectivity in vaccinated individuals: a nasal photodisinfection clinical trial by Ondine Biomedical conducted at Clínica Universidad de Navarra, Spain appeared first on TOP News Austria – News from Austria and around the world.